Research-use notice: This review discusses published research and regulatory information. It is not medical advice or a recommendation for human use. First Due Biotech products are offered strictly for laboratory research use only and are not for human consumption.
Executive assessment
BPC-157 is a chemically synthesized linear 15-amino-acid peptide, GEPPPGKPADDAGLV, commonly described as a stable gastric pentadecapeptide. Its synthetic identity is established; its frequently claimed status as an endogenous human peptide is not. No independently replicated modern isolation, sequence-confirmed endogenous free 15-mer, identified parent gene or protein, or validated human-proteome match was located. P004–P006
The preclinical literature spans gastrointestinal injury, tendon, ligament, muscle, bone, wound, nerve, vascular, hepatic, renal, and other models. Its breadth is offset by unusually high author-network concentration, repeated use of related experimental platforms, small samples, incomplete masking and power reporting, positive-outcome dominance, and limited outside replication.
No completed randomized human study is published in full. Two controlled programs are abstract-only. Three complete administration publications are tiny uncontrolled series from one private-clinic network. No published study establishes human structural tissue repair, comparative efficacy, pharmacokinetics, or an adequately characterized adverse-event rate. P004, P010–P017
The evidence-weighted conclusion is that BPC-157 has demonstrable biological activity in several nonhuman systems, but human therapeutic benefit and long-term safety remain unestablished.
Evidence-strength summary
| Area | Strength | Central limitation |
|---|---|---|
| Synthetic peptide identity | High | Product-specific quality can vary |
| Endogenous human origin | Very low / unverified | No modern molecular confirmation |
| Direct molecular target | Absent | Pathway association without validated binding target |
| Animal PK/ADME | Moderate | One main rat/dog program; no human bridge |
| Human PK | Absent / insufficient | Abstract-level nondetectability and unresolved registry |
| Gastric-lesion reduction | Low-to-moderate preclinical | Animal injury endpoints; no established human efficacy |
| Tendon healing | Low preclinical | Independent repaired-Achilles result was mixed/null |
| Ligament, muscle, bone, nerve, fistula | Very low | Mostly single-network animal research |
| Endothelial activity | Low-to-moderate mechanistic | No in-vivo human outcome |
| Human symptom evidence | Very low | Tiny uncontrolled series |
| Short preclinical toxicology | Low-to-moderate hazard screening | Short duration and incomplete package |
| Chronic human safety | Absent | No adequate denominator or follow-up |
| Regulatory non-approval | High | Status requires periodic review |
| WADA prohibition | High | Explicit current official listing |
Identity, origin, and nomenclature
BPC-157 is a linear synthetic pentadecapeptide with sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. PubChem reports formula C62H98N16O22 and molecular mass approximately 1,419.5 g/mol. P005
Aliases include BPC 157, BPC-157, Bepecin, PL 14736, PL-14736, PL-10, and PLD-116. FDA describes “BPC-157” as a common rather than standardized USAN name and has documented confusion among free-base, acetate, and other salt descriptions. P004
The “Body Protection Compound” narrative originates in a Zagreb program that described an approximately 40-kDa bioactive gastric-juice fraction and later a 15-residue activity-bearing fragment. The foundational evidence is a 1993 overview and patent history, not modern proteomic identification. P006
The following remain unresolved:
- whether the exact free 15-mer normally exists in humans;
- the identity of a parent gene or protein;
- reproducible tandem-mass-spectrometry confirmation from human tissue or fluid;
- the relationship between the historical 40-kDa fraction and the synthetic peptide;
- whether reported gastric-juice stability translates into human bioavailability.
Proposed mechanisms
The literature associates BPC-157 with nitric-oxide signaling, endothelial behavior, angiogenesis, VEGFR2–Akt–eNOS signaling, FAK/paxillin activity, cell migration, growth-hormone-receptor expression, inflammatory markers, and oxidative-stress measures.
Independent Taiwan-based work reported tendon-cell outgrowth and migration and VEGFR2-associated angiogenic activity. A 2026 ex-vivo study reported endothelium- and nitric-oxide-dependent relaxation in human internal-mammary-artery rings. P018, P020–P021
These are pathway or tissue-level observations. No direct receptor has been validated through binding, occupancy, genetic loss-of-function, or convergent pharmacology sufficient to establish a single primary molecular target. Human-tissue vasorelaxation is not participant exposure or evidence of clinical cardiovascular benefit.
Pharmacokinetics and pharmacodynamics
The principal published ADME study used rats and dogs. Intact parent peptide disappeared rapidly, while total radioactivity persisted longer through labeled metabolites. Long radiolabel persistence should not be represented as the intact peptide’s half-life. P007
Human PK remains essentially absent. A local healthy-volunteer abstract reported concentrations that were undetectable or largely below quantification, without sufficient assay and time-course detail. NCT02637284 planned systemic safety and PK endpoints but has unknown status and no posted results. The two-person systemic publication did not measure drug concentrations. P004, P010, P014–P015
No adequate human dataset establishes absorption, bioavailability, intact-peptide half-life, distribution, metabolism, clearance, excretion, dose proportionality, or exposure-response.
Human evidence
Controlled studies available only as abstracts
Healthy-volunteer Phase I report. Veljača and colleagues reported a controlled local-exposure study in 32 healthy men. The meeting abstract does not provide a complete assay validation, participant flow, adverse-event table, or interpretable systemic PK profile. P004, P010
Ulcerative-colitis Phase II report. Ruenzi and colleagues reported a multicenter randomized, double-blind placebo-controlled study involving 53 participants. Only a meeting abstract is accessible. FDA reconstructed the between-group estimate as inconclusive, with uncertainty crossing no effect. Complete randomization, masking, baseline, attrition, endpoint, and safety reporting remain unavailable. P004, P011
Neither abstract supports a claim of proven clinical efficacy or established safety.
Published uncontrolled human reports
Knee pain. A retrospective private-clinic report reviewed 17 records and contacted 16 people months later. Twelve reportedly received BPC-157 alone. Eleven of those twelve recalled significant improvement. There was no comparator, prospective baseline, validated function scale, blinded assessment, imaging, histology, or structural-repair endpoint. P012
Interstitial cystitis. A 12-woman uncontrolled series reported large self-rated symptom improvements. It lacked a comparator, blinding, preregistration, objective confirmation, and independent replication. P013
Two-person laboratory observation. Two previously exposed adults showed no clinically significant acute change in selected routine laboratories or vital signs during brief follow-up. The report had no comparator, exposure-naïve participant, concentration assay, delayed follow-up, or statistical power for uncommon toxicity. P014
No genuine peer-reviewed single-patient therapeutic or adverse case report was identified. These three publications cannot establish tissue repair, comparative efficacy, a safe human exposure, PK, or a general adverse-event rate.
Registries and ongoing research
| Record | Status at cutoff | Evidentiary meaning |
|---|---|---|
| NCT02637284 [P015] | Unknown; no posted results | Planned systemic safety/PK study; completion cannot be assumed |
| NCT07437547 [P016] | Recruiting | Controlled acute-hamstring-strain question; no results |
| NCT07752381 [P017] | Completed, retrospectively registered; no posted results | Uncontrolled protocol record; no efficacy conclusion |
Musculoskeletal evidence
Achilles tendon and tendon-to-bone models
The originating network reported improved histology, biomechanics, and functional measures in rat Achilles transection and detachment models. Starešinić et al. combined a transected-rat-tendon model with tendon-cell observations; subsequent papers extended the program to tendon-to-bone healing and corticosteroid interactions. P019, P003
Chang et al. independently reported enhanced rat tendon-explant outgrowth, cell survival, and migration, later connecting the response to FAK/paxillin and growth-hormone-receptor expression. Hsieh et al. reported VEGFR2-related angiogenic activity in cell and animal models. P020–P021
Biçer et al. provided a particularly important outside-network test in 2026. In repaired rat Achilles tendons, selected histologic changes were reported, but corrected maximum load-to-failure and composite histology outcomes were not improved. P022
This creates a mixed replication picture: biological and histologic signals are plausible, while robust functional and mechanical repair remains uncertain.
Ligament, muscle, and bone
A rat medial-collateral-ligament paper reported improved healing measures, but no independent replication or human structural outcome was located. P023
Originating-network papers report findings after quadriceps transection, muscle crush, corticosteroid-impaired repair, myotendinous disruption, muscle-to-bone reattachment, and bone defects. These results remain preclinical and mostly unreplicated outside the network. The literature does not establish repair of human tendon, ligament, muscle, cartilage, or bone.
Gastrointestinal evidence
Gastric-lesion reduction is among the more repeatedly studied preclinical findings. Multiple Zagreb studies reported smaller lesions across stress, alcohol, NSAID, and other injury models.
Veljaca et al., working at Parke-Davis/Warner-Lambert, reported reduced TNBS-induced colonic damage and myeloperoxidase after systemic pretreatment in rats, while the tested local arm was null. P024
This represents meaningful independent preclinical convergence, but it involved prophylaxis in an acute animal injury model with short follow-up. It does not establish treatment of human inflammatory bowel disease. The available human ulcerative-colitis report is abstract-only and inconclusive. P004, P011
Other organ systems
Preclinical publications report effects in wound, skin, peripheral-nerve, spinal-cord, vascular-occlusion, fistula, anastomosis, liver, kidney, urinary, ocular, pulmonary, and behavioral models.
Most dramatic functional claims in these areas originate from the same Zagreb network and have not received direct outside replication. Studies often extend a shared injury, nitric-oxide, occlusion, or fistula platform across organs. This produces scientific breadth without equivalent independent confirmation.
Independent Korean programs have reported antinociceptive effects in acute rodent incision and formalin models. These results concern pain behavior, not tissue healing or human analgesia.
Author-network concentration and replication
The evidence dossier estimated that approximately 79% of PubMed title/abstract records involved Sikirić, Seiwerth, or Rucman, and roughly 84% of prioritized non-musculoskeletal organ-system records belonged to the Zagreb network or close collaborators. Sixteen of 23 prioritized musculoskeletal records were from the core network.
These are transparent estimates rather than a formal bibliometric census. They nevertheless require a major interpretive control: multiple publications from related investigators and experimental platforms are network extensions, not independent replications.
Outside-network convergence is clearest for limited gastric-lesion reduction, wound/angiogenic activity, endothelial bioactivity, and acute antinociception. Fistula closure, ligament regeneration, major functional muscle repair, nerve or spinal-cord recovery, major-vessel collateral recruitment, and liver or kidney recovery remain largely unreplicated.
Safety and toxicology
Xu et al. reported acute and 28-day rat/dog studies, local tolerance, a standard genotoxicity battery, and one rat embryo-fetal protocol. Standard genotoxicity tests were negative and no embryo-fetal signal was reported in that protocol. P008
FDA’s review identified coagulation, liver-enzyme, glucose, triglyceride, hematology, and creatinine changes; incomplete histopathology presentation; route limitations; and no carcinogenicity program. P004
The published package does not adequately address:
- chronic toxicity or carcinogenicity;
- tumor promotion in the context of angiogenic signaling;
- fertility, pre/postnatal development, or juvenile exposure;
- immunogenicity, aggregation, and cross-reactivity;
- route-matched product impurities, sterility, endotoxin, and residual solvents;
- uncommon or delayed human adverse effects.
FDA identified three spontaneous reports through December 2025 involving injection-site inflammation, dyspnea requiring emergency evaluation, and reproducible hyperpigmentation after combination exposure. Causality and ingredient attribution were uncertain. These reports do not establish incidence or causation, but they also prevent categorical statements that no human adverse events have been reported. P004
Regulatory and anti-doping status
No regulator-approved BPC-157 medicine for human therapeutic use was identified. FDA states that neither free base nor acetate is a component of an approved drug and has documented identity, quality, safety, PK, and efficacy deficiencies during compounding review. P004
Health Canada describes marketed BPC-157 products as unauthorized. Australia’s TGA describes BPC-157 as unapproved and controls it under Schedule 4. P027–P028
The WADA 2026 Prohibited List explicitly names BPC-157 under S0 Non-Approved Substances and prohibits it at all times. P009
Major limitations
- Most publications originate from one interconnected investigator network.
- Related models and cohorts expand the paper count without independent confirmation.
- Animal samples are commonly small, with limited masking, power, and multiplicity reporting.
- Null and negative results are scarce, increasing selective-reporting concern.
- Several older papers, supplements, theses, and abstracts have incomplete methods.
- Histology, lesion area, biomarkers, and cell migration are often translated into broad healing claims.
- No completed randomized human study is published in full.
- Human PK, target pharmacology, and long-term safety remain unresolved.
- Product form, impurities, aggregation, sterility, and endotoxin may differ across materials.
- Preclinical breadth does not provide an evidentiary bridge to human therapeutic benefit.
Common unsupported claims
| Claim | Evidence verdict |
|---|---|
| “BPC-157 naturally occurs in human gastric juice.” | Exact endogenous identity remains unverified. |
| “Oral bioavailability follows from gastric stability.” | Stability assertions do not establish human absorption or exposure. |
| “Human Phase I and II trials proved safety and efficacy.” | Only meeting abstracts are accessible; the UC estimate was inconclusive. |
| “It repairs human tendons or ligaments.” | Structural repair evidence is animal-only; independent Achilles replication was mixed/null. |
| “The intact peptide has a long half-life.” | Long radiolabel persistence reflects metabolites; no human half-life is established. |
| “There are no adverse effects.” | Human data are inadequate, and uncertain-causality spontaneous reports exist. |
| “FDA banned it in 2023.” | FDA compounding-risk and Bulks-List processes are not therapeutic approval and should be described precisely. |
Research priorities
- Independent molecular identification of any endogenous counterpart
- Direct target and binding-pharmacology studies
- Validated route-specific human PK
- Complete publication of prior controlled studies
- Preregistered, adequately powered human trials with validated outcomes
- Multicenter independent animal replication before broad translation
- Chronic, carcinogenicity, reproductive, immunogenicity, and safety-pharmacology programs
- Product-quality standards for identity, related substances, aggregates, sterility, and endotoxin
- Publication of current registry outcomes regardless of result
Conclusion
BPC-157 is a defined synthetic research peptide with broad preclinical activity. The strongest areas show limited cross-laboratory convergence, especially in experimental gastric injury and selected cellular or vascular mechanisms.
The overall evidence base remains constrained by author concentration, limited independent replication, sparse negative findings, incomplete human trial publication, absent human PK, and inadequate long-term safety characterization.
Published human observations are worth documenting but do not establish therapeutic efficacy or structural tissue healing. The correct scientific position is therefore neither dismissal nor clinical endorsement: BPC-157 is a biologically active experimental compound whose human effects and risks remain largely unresolved.